Evidence map›Paper›PMID 37391777›Full record

ArticleJournal of translational medicine2023

Targeting RNA-binding protein HuR to inhibit the progression of renal tubular fibrosis.

Zhimin Huang, Simeng Liu, Anna Tang, Xiaoqing Wu, Jeffrey Aube, Liang Xu, Yufeng Huang

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. HuR ablation destabilizesFrontiers in immunology · 2025
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Zhimin Huang *Division of Nephrology & Hypertension, Department of Internal Medicine, University of Utah Health Science, Wintrobe Rm 403, 26 N Medical Dr., Salt Lake City, UT, 84132, USA.
Simeng Liu *Division of Nephrology & Hypertension, Department of Internal Medicine, University of Utah Health Science, Wintrobe Rm 403, 26 N Medical Dr., Salt Lake City, UT, 84132, USA.
Anna TangDivision of Nephrology & Hypertension, Department of Internal Medicine, University of Utah Health Science, Wintrobe Rm 403, 26 N Medical Dr., Salt Lake City, UT, 84132, USA.
Xiaoqing WuDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS, USA.
Jeffrey AubeDepartment of Chemical Biology and Medical Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Liang XuDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS, USA.
Yufeng HuangDivision of Nephrology & Hypertension, Department of Internal Medicine, University of Utah Health Science, Wintrobe Rm 403, 26 N Medical Dr., Salt Lake City, UT, 84132, USA. Yufeng.huang@hsc.utah.edu.ORCID 0000-0001-9186-5269
University of Utah · USUniversity of Kansas · USUniversity of North Carolina at Chapel Hill · US

Funding

Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted TherapyR01CA243445 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI DIXON, DAN ALAN, XU, LIANG · 2019 to 2023
$3.0M
Novel therapeutic strategy for renal fibrosis by targeting RNA-binding protein HuRR01DK123727 · NIDDK · UNIVERSITY OF UTAH · PI HUANG, YUFENG · 2020 to 2024
$1.8M
NCI NIH HHS R01 CA243445NIDDK NIH HHS R01 DK123727
6 · The paper itself

Abstract

backgroundUpregulation of an RNA-binding protein HuR has been implicated in glomerular diseases. Herein, we evaluated whether it is involved in renal tubular fibrosis.

methodsHuR was firstly examined in human kidney biopsy tissue with tubular disease. Second, its expression and the effect of HuR inhibition with KH3 on tubular injury were further assessed in a mouse model induced by a unilateral renal ischemia/reperfusion (IR). KH3 (50 mg kg

resultsHuR significantly increases at the site of tubular injury both in progressive CKD in patients and in IR-injured kidneys in mice, accompanied by upregulation of HuR targets that are involved in inflammation, profibrotic cytokines, oxidative stress, proliferation, apoptosis, tubular EMT process, matrix remodeling and fibrosis in renal tubulointerstitial fibrosis. KH3 treatment reduces the IR-induced tubular injury and fibrosis, accompanied by the remarkable amelioration in those involved pathways. A panel of mRNA array further revealed that 519 molecules in mouse kidney following IR injury changed their expression and 71.3% of them that are involved in 50 profibrotic pathways, were ameliorated when treated with KH3. In vitro, TGFβ1 induced tubular HuR cytoplasmic translocation and subsequent tubular EMT, which were abrogated by KH3 administration in cultured HK-2 cells.

conclusionsThese results suggest that excessive upregulation of HuR contributes to renal tubulointerstitial fibrosis by dysregulating genes involved in multiple profibrotic pathways and activating the TGFß1/HuR feedback circuit in tubular cells. Inhibition of HuR may have therapeutic potential for renal tubular fibrosis.

Indexed as

Kidney DiseasesAnimalsApoptosisCytokinesCytoplasmHumansKidneyMiceCytokinesChronic kidney diseaseHuR inhibitorIschemia–reperfusionRenal fibrosisRNA-binding protein

Identifiers

PMID37391777
PMCPMC10311833
OpenAlexW4382777458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.